• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Edwards Lifesciences wins FDA approval for Inspiris Resilia valve

Edwards Lifesciences wins FDA approval for Inspiris Resilia valve

July 5, 2017 By Brad Perriello

Edwards Lifesciences Inspiris Resilia surgical aortic valve replacementEdwards Lifesciences (NYSE:EW) said today that it won pre-market approval from the FDA for its Inspiris Resilia surgical aortic valve replacement, claiming it as “the first in a new class of resilient heart valves.”

Irvine, Calif.-based Edwards said the valve uses its Resilia tissue technology, which is designed to inhibit calcification and improve hemodynamic performance and dry storage. The company also touted Inspiris Resilia’s VFit expandable frame, which features size markers for later valve-in-valve procedures, and the underlying Carpentier-Edwards Perimount valve design.

Edwards said it’s planning for a full U.S. launch early next year for the Inspiris Resilia, which has been on the market in Europe earlier this year after winning CE Mark approval in September 2016.

“Building on Edwards’ 40 years of leadership in tissue valve technology, the Inspiris valve featuring Resilia tissue has been in development for more than a decade and may be uniquely suited for future valve-in-valve procedures,” surgical heart valve VP Bernard Zovighian said in prepared remarks. “In partnership with surgeons, Edwards is committed to continually developing transformative surgical innovations that benefit patients.”

The FDA nod was based on two-year data from the 689-patient Commence study, which Edwards said showed “no cases of structural valve deterioration, valve thrombosis or nonstructural valve dysfunction.”

“The Inspiris valve sets a new benchmark for surgical aortic valve replacement, providing patients, particularly those with active lifestyles, with a resilient tissue valve that is built on Edwards’ legacy of excellence in heart valve innovations,” added principal investigator Dr. John Puskas of the Icahn School of Medicine at New York City’s Mount Sinai hospital.

“With the addition of VFit technology, featuring the unique expandable design feature, the Inspiris valve provides an ideal foundation for heart valve patients, both now and in the future,” said Dr. Joseph Bavaria of the University of Pennsylvania.

Filed Under: Food & Drug Administration (FDA), Regulatory/Compliance, Replacement Heart Valves Tagged With: Edwards Lifesciences

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy